HGEN - Humanigen gains as CEO more than doubles stake

Clinical-stage biotech, Humanigen (NASDAQ:HGEN) has added ~6% in the pre-market after two of the senior officers of the company, including Chief Executive Cameron Durrant, disclosed insider purchases through SEC filings on Friday. On Mar. 02, Cameron has bought 40,000 company shares at $2.34 apiece to increase his holdings by ~133% to 70,000. On the same day, executing his further insider transaction at Humanigen (HGEN), Chief Commercial Officer, Edward P. Jordan, has purchased 12,500 shares at $2.32 per unit. A former senior executive at Johnson and Johnson (NYSE:JNJ), GlaxoSmithKline (NYSE:GSK), and Merck (NYSE:MRK), Dr. Durrant has served as the company CEO since 2016. Before joining, Humanigen (HGEN) in 2020, Jordan served as Senior Vice President of DBV Technologies (NASDAQ:DBVT) from 2016, the company disclosed in its latest 10-K filing.

For further details see:

Humanigen gains as CEO more than doubles stake